Supplementary Table S10. Invasive nevi and melanoma patient characteristics, median survival, and Multivariate Cox Regression Modeling.

Patient Characteristics: Invasive Nevi & Melanoma		LOR	ALP	No Benzo	Overall	P-value
	N	130 (18.6)	76 (10.9)	494 (70.6)	700 (100%)	
Sex	Female	54 (41.5%)	43 (56.6%)	231 (46.8%)	328 (46.9%)	0.113
	Male	76 (58.5%)	33 (43.4%)	263 (53.2%)	372 (53.1%)	
Grade (Clinical)	I			1 (0.2%)	1 (0.1%)	0.707
	III		1 (1.3%)	2 (0.4%)	3 (0.4%)	
	IV	1 (0.8%)		1 (0.2%)	2 (0.3%)	
	Not Reported	129 (99.2%)	75 (98.7%)	490 (99.2%)	694 (99.1%)	
Grade (Pathological)	I			1 (0.2%)	1 (0.1%)	0.527
	III		1 (1.3%)	1 (0.2%)	2 (0.3%)	
	IV	1 (0.8%)		1 (0.2%)	2 (0.3%)	
	Not Reported	129 (99.2%)	75 (98.7%)	491 (99.4%)	695 (99.3%)	
Stage (Clinical)	0			1 (0.2%)	1 (0.1%)	<.001
	I	32 (24.6%)	34 (44.7%)	133 (27.0%)	199 (28.5%)	
	II	20 (15.4%)	14 (18.4%)	47 (9.5%)	81 (11.6%)	
	III	6 (4.6%)	4 (5.3%)	9 (1.8%)	19 (2.7%)	
	IV	4 (3.1%)	1 (1.3%)	13 (2.6%)	18 (2.6%)	
	Not Reported	68 (52.3%)	23 (30.3%)	290 (58.8%)	381 (54.5%)	
Stage (Pathological)	0		1 (1.3%)	3 (0.6%)	4 (0.6%)	0.002
	I	36 (27.7%)	28 (36.8%)	219 (44.4%)	283 (40.5%)	
	II	16 (12.3%)	15 (19.7%)	70 (14.2%)	101 (14.4%)	
	III	18 (13.8%)	13 (17.1%)	44 (8.9%)	75 (10.7%)	
	IV	1 (0.8%)		9 (1.8%)	10 (1.4%)	
	Not Reported	59 (45.4%)	19 (25.0%)	148 (30.0%)	226 (32.3%)	
Overall Survival Indicator	Alive	49 (37.7%)	49 (64.5%)	297 (60.1%)	395 (56.4%)	<.001
	Dead	81 (62.3%)	27 (35.5%)	197 (39.9%)	305 (43.6%)	
Progression-Free Survival Indicator	No Progression	43 (33.1%)	47 (61.8%)	287 (58.1%)	377 (53.9%)	<.001
	Progression	87 (66.9%)	29 (38.2%)	207 (41.9%)	323 (46.1%)	

Overall Survival (OS)	Median Surv. (95% CI)	Sample: Invasive Nevi & Melanoma	Log Rank P-value
Total	144.7 (120.0, 193.7)	E=305 C=395 T=700	p= <.001
ALP	NR (69.4, NR)	E=27 C=49 T=76	
LOR	72.2 (54.1, 97.4)	E=81 C=49 T=130	
No Benzo	193.7 (150.3, NR)	E=197 C=297 T=494	

Progression-Free Survival (PFS)	Median Surv. (95% CI)	Sample: Invasive Nevi & Melanoma	Log Rank P-value
Total	132.7 (103.7, 165.9)	E=323 C=377 T=700	p= <.001
ALP	142.3 (69.4, NR)	E=29 C=47 T=76	
LOR	44.7 (34.4, 63.5)	E=87 C=43 T=130	
No Benzo	192.2 (134.3, NR)	E=207 C=287 T=494	

Overall Survival (OS)

Predictors: Cohort, Sex, Clinical Grade, and Clinical Stage

Cohort	HR (95% CI)	P-value
No Benzo	Ref.	<.0001
ALP	1.194 (0.791 – 1.803)	0.3984
LOR	1.978 (1.519 – 2.576)	<.0001

Progression-Free Survival (PFS)

No Benzo	Ref.	<.0001
ALP	1.205 (0.807 – 1.799)	0.3623
LOR	2.195 (1.699 – 2.835)	<.0001

E= event, C= censored, T= Total